A Phase I, Single-center, Open-label Fixed-sequence Study to Assess the Effects of PRN1008 on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Healthy Adults

Trial Profile

A Phase I, Single-center, Open-label Fixed-sequence Study to Assess the Effects of PRN1008 on the Pharmacokinetics of Midazolam, a CYP3A4 Substrate, in Healthy Adults

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2016

At a glance

  • Drugs PRN 1008 (Primary) ; Midazolam
  • Indications Rheumatoid arthritis
  • Focus Pharmacokinetics
  • Sponsors Principia Biopharma
  • Most Recent Events

    • 27 Feb 2015 Status changed from recruiting to completed, according to Australian New Zealand Clinical Trials Registry record.
    • 19 Dec 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top